Tarter Krinsky & Drogin’s China Practice assists U.S. and Chinese companies and investors entering or operating in the U.S. and in China. From emerging businesses to global corporations, our clients do business in a variety of industries including the life sciences, chemical, products, food and beverage areas.
Our goal is to develop a successful, long-term relationship with our clients and to work closely with you to understand your legal and business issues. With more than 15 distinct practice areas, we can provide comprehensive solutions and guide you through all aspects of complex global transactions from licensing issues and outsourcing to regulatory requirements, intellectual property issues and leasing.
Working with trusted local counsel, our attorneys seamlessly navigate between Chinese and American culture to provide you service in both the United States and in China.
Our services include:
|Braginsky, Philip Partner and Co-Chair of Intellectual Property Group and Pharmaceutical and Biologics Practice and China Practice||Partner and Co-Chair of Intellectual Property Group and Pharmaceutical and Biologics Practice and China Practice||212.216.8065|
|Gaynor, Alan S. Partner||Partner||212.216.1136|
|Lin, Rachel J. Counsel||Counsel||212.216.1152|
|Rosenberg, Mark J. Partner and Co-Chair of Reputation Management Practice||Partner and Co-Chair of Reputation Management Practice||212.216.1127|
|Shravah, Aasheesh Counsel||Counsel||212.216.1132|
|Xia, Jing Partner and Co-Chair of Pharmaceutical and Biologics Practice and China Practice||Partner and Co-Chair of Pharmaceutical and Biologics Practice and China Practice||212.216.1158|
Bloomberg's Big Law Business highlighted Tarter Krinsky & Drogin’s recent lawyer promotions in its Wake Up Call column.
Over the past few years, owners of U.S. patents and trademarks have used the appearance of Chinese companies at a trade show as infringement "traps." These patent owners have commenced infringement cases against Chinese companies based on those companies' activities at the trade show.
In December 2016, the FDA published an industry guidance related to the Biologics Price Competition and Innovation Act. This guidance offers suggestions to sponsors on the design and use of clinical pharmacology studies to support a claim of biosimilarity to a reference product.
Over the past two years, owners of U.S. patents have used Chinese companies' appearances at a trade show as a patent infringement "trap."